Belknap SM, Aslam I, Kiguradze T, Temps WH, Yarnold PR, Cashy J, et al. Adverse event reporting in clinical trials of finasteride for androgenic alopecia: a meta-analysis. JAMA Dermatol 2015;151(6):600-6. http://www.ncbi.nlm.nih.gov/pubmed/25830296
Biggar RJ, Andersen EW, Wohlfahrt J, Melbye M. Spironolactone use and the risk of breast and gynecologic cancers. Cancer Epidemiol 2013;37(6):870-5. https://www.ncbi.nlm.nih.gov/pubmed/24189467
Girijala RL, Riahi RR, Cohen PR. Platelet-rich plasma for androgenic alopecia treatment: A comprehensive review. Dermatol Online J 2018;24(7). https://www.ncbi.nlm.nih.gov/pubmed/30261560
Mackenzie IS, Macdonald TM, Thompson A, Morant S, Wei L. Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. BMJ 2012;345:e4447. https://www.ncbi.nlm.nih.gov/pubmed/22797844
Nguyen DD, Marchese M, Cone EB, Paciotti M, Basaria S, Bhojani N, et al. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. JAMA Dermatol 2021;157(1):35-42. https://www.ncbi.nlm.nih.gov/pubmed/33175100
Wei C, Bovonratwet P, Gu A, Moawad G, Silverberg JI, Friedman AJ. Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis. J Am Acad Dermatol 2020;83(4):1021-7. https://www.ncbi.nlm.nih.gov/pubmed/32446820
